Tenax Therapeutics (TENX) Non-Current Assets (2011 - 2024)
Tenax Therapeutics recorded quarterly Non-Current Assets of $1117.0 in Q3 2024, little changed quarter-over-quarter from $1117.0 in Q2 2024, and down 80.82% year-over-year from $5823.0 in Q4 2023.
Tenax Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $1117.0 for Q3 2024.
- In Q3 2024, Non-Current Assets fell 80.82% year-over-year to $1117.0; the TTM figure through Jun 2025 stood at $1117.0 (down 87.67% YoY), while the FY2023 annual figure was $1000.0, down 99.49% from the prior year.
- Non-Current Assets came in at $1117.0 for Q3 2024 at Tenax Therapeutics, roughly flat from $1117.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $352954.0 in Q2 2021 to a low of -$28426.0 in Q1 2023.
- A 5-year average of $127908.6 and a median of $99181.0 in 2020 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 556.27% in 2022 and tumbled 110.08% in 2023, its largest moves.
- Tenax Therapeutics' Non-Current Assets stood at $73185.0 in 2020, then surged by 299.31% to $292235.0 in 2021, then tumbled by 32.85% to $196244.0 in 2022, then plunged by 99.49% to $1000.0 in 2023, then grew by 11.7% to $1117.0 in 2024.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1117.0, $1117.0, and $1117.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1,117.00 |
| Jun 30, 2024 | 1,117.00 |
| Mar 31, 2024 | 1,117.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 5,823.00 |
| Jun 30, 2023 | 6,792.00 |
| Mar 31, 2023 | -28,426.00 |
| Dec 31, 2022 | 196,244.00 |
| Sep 30, 2022 | 225,427.00 |
| Jun 30, 2022 | 253,941.00 |
| Mar 31, 2022 | 281,948.00 |
| Dec 31, 2021 | 292,235.00 |
| Sep 30, 2021 | 328,367.00 |
| Jun 30, 2021 | 352,954.00 |
| Mar 31, 2021 | 42,962.00 |
| Dec 31, 2020 | 73,185.00 |
| Sep 30, 2020 | 99,181.00 |
| Jun 30, 2020 | 138,792.00 |
| Mar 31, 2020 | 156,488.00 |
| Dec 31, 2019 | 184,442.00 |
| Sep 30, 2019 | 212,071.00 |
| Jun 30, 2019 | 239,190.00 |
| Mar 31, 2019 | 265,784.00 |
| Dec 31, 2018 | 16,960.00 |
| Sep 30, 2018 | 312,962.00 |
| Jun 30, 2018 | 316,123.00 |
| Mar 31, 2018 | 1.32 Mn |
| Dec 31, 2017 | 1.83 Mn |
| Sep 30, 2017 | 2.34 Mn |
| Jun 30, 2017 | 4.45 Mn |
| Mar 31, 2017 | 6.37 Mn |
| Dec 31, 2016 | 9.71 Mn |
| Sep 30, 2016 | 52.04 Mn |
| Jun 30, 2016 | 53.96 Mn |
| Dec 31, 2015 | 52.43 Mn |
| Apr 30, 2013 | 1.34 Mn |
| Jan 31, 2013 | 1.39 Mn |
| Oct 31, 2012 | 1.42 Mn |
| Jul 31, 2012 | 1.48 Mn |
| Apr 30, 2012 | 1.51 Mn |
| Jan 31, 2012 | 1.56 Mn |
| Oct 31, 2011 | 1.68 Mn |
| Jul 31, 2011 | 1.67 Mn |
| Apr 30, 2011 | 1.29 Mn |